DA-11004

DA-11004 is an orally active NADP-dependent isocitrate dehydrogenase (IDPc) inhibitor with an IC₅₀ of 1.49 μM. DA-11004 reduces NADPH production, decreases plasma NADPH levels and plasma free fatty acid levels. DA-11004 lowers plasma glucose levels, inhibits fatty acid synthesis in adipose tissue, reduces weight gain and decreases epididymal and retroperitoneal fat content. DA-11004 exerts antidiabetic effects in mice fed a high-fat and high-sugar diet. DA-11004 can be used for research on obesity and type 2 diabetes^[1]. In Vivo:DA-11004 (30-100 mg/kg; p.o.; daily; 8 weeks) dose-dependently inhibits diet-induced obesity in male C57BL/6J mice, with the 100 mg/kg oral daily dose for 8 weeks normalizing body weight, adipose tissue weights, and plasma glucose levels, while reducing plasma triglycerides and free fatty acids via inhibition of IDPc activity and NADPH production^[1].